| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 88.57M | 79.91M | 65.42M | 45.52M | 45.18M | 41.14M |
| Gross Profit | 67.08M | 59.09M | 48.12M | 32.49M | 33.44M | 30.27M |
| EBITDA | -16.22M | -16.57M | -22.83M | -36.57M | -28.37M | -12.48M |
| Net Income | -17.29M | -27.14M | -32.96M | -47.08M | -36.08M | -24.28M |
Balance Sheet | ||||||
| Total Assets | 106.11M | 94.65M | 107.65M | 114.11M | 133.56M | 55.95M |
| Cash, Cash Equivalents and Short-Term Investments | 62.14M | 52.76M | 66.45M | 77.41M | 115.58M | 38.08M |
| Total Debt | 71.52M | 73.34M | 72.39M | 69.77M | 49.85M | 52.86M |
| Total Liabilities | 86.68M | 86.63M | 87.00M | 79.33M | 60.06M | 203.78M |
| Stockholders Equity | 19.44M | 8.01M | 20.65M | 34.78M | 73.50M | -6.41M |
Cash Flow | ||||||
| Free Cash Flow | -16.23M | -18.25M | -19.87M | -37.47M | -24.96M | -21.67M |
| Operating Cash Flow | -16.09M | -17.95M | -19.70M | -36.87M | -24.58M | -21.61M |
| Investing Cash Flow | 3.16M | 8.99M | 23.03M | 23.80M | -85.40M | -10.77M |
| Financing Cash Flow | 22.95M | 4.33M | 8.13M | 490.00K | 102.53M | 55.01M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | $336.61M | 24.10 | 7.64% | ― | 6.15% | -54.24% | |
| ― | $357.86M | 219.56 | ― | ― | 251.26% | ― | |
| ― | $472.60M | ― | ― | ― | ― | ― | |
| ― | $346.69M | ― | -176.94% | ― | 23.32% | 23.29% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | $352.29M | ― | -11.66% | ― | 27.68% | 20.87% | |
| ― | $285.55M | -3.64 | -102.61% | ― | 5.94% | 25.18% |
In the latest earnings call, NeuroPace, Inc. demonstrated a strong performance with record revenue and improved gross margins, despite facing challenges such as increased operating expenses and a higher net loss. The company also shared positive clinical trial data, although the NAUTILUS trial did not meet its primary effectiveness endpoint.
Neuropace, Inc. is conducting a study titled ‘RNS System Feasibility Study of Thalamocortical Brain-Responsive Neurostimulation for the Treatment of Lennox-Gastaut Syndrome’. The study aims to assess the safety and effectiveness of brain-responsive neurostimulation in reducing generalized seizures in patients aged 12 and older with Lennox-Gastaut Syndrome (LGS) who do not respond to antiseizure medications. This research is significant as it seeks to expand the use of the RNS System for treating medically intractable LGS.
NeuroPace, Inc., based in Mountain View, California, is a medical device company specializing in innovative solutions for epilepsy treatment, notably through its RNS System, a brain-responsive platform that offers personalized, real-time seizure management. In its latest earnings report for the second quarter of 2025, NeuroPace announced a record quarterly revenue of $23.5 million, marking a 22% increase year-over-year. The company also raised its full-year revenue guidance to between $94 million and $98 million, reflecting strong market performance and strategic advancements.